2,137 press releases in English indexed under biotech & pharma.
CLINUVEL PHARMACEUTICALS LTD announced its tenth consecutive annual profit and further rise in free cash in the financial year ended 30 June 2026 (FY2026).
GENEVA, Aug. 27, 2026 -- MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics, or the Company), a global leader in scalable precision neurotherapeutics, today announced the publication of its 2026 half-year report and provided a corporate update. Key Highlights...
DUBLIN, Aug. 27, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private offering (the "offering") by Jazz Investments I...
Results Highlights for Interim Results ended 30 June 2026 Revenue reached RMB1,006.5 million, increasing by 21.0% YoY Gross profit amounted to RMB341.7 million, increasing by 0.7% YoY Gross profit margin was 34.0% HONG KONG, Aug. 27, 2026 -- On August 26, 2026, Viva Biotech...
New York, New York and New Orleans, Louisiana--(August 26, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors who purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26,...
New York, New York--(August 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) between March 9, 2026 and June 24, 2026, inclusive (the "Class Period"), of the important October 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased ARS Pharmaceuticals securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
New York, New York--(August 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aardvark Therapeutics, Inc. (NASDAQ: AARD): (i) common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the "Registration Statement") issued in connection with Aardvark's February 13, 2025 initial public offering ("IPO"); and/or (ii) securities between February 13, 2025 and May 14, 2026, both dates inclusive (the "Class...
SHANGHAI and LAGUNA HILLS, Calif., Aug. 26, 2026 -- The complete results of AIntibody, the first international AI antibody design competition, have now been formally published in Nature Biotechnology. Widely regarded as the field's most rigorous test — every entry validated...
NEW YORK, Aug. 26, 2026 -- The law firm of Kirby McInerney LLP is investigating potential claims against EyePoint Pharmaceuticals (“EyePoint” or the “Company”) (NASDAQ: EYPT). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired EyePoint securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below, to learn more about your rights.
NEW YORK, Aug. 26, 2026 -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
New York, New York--(August 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.SO WHAT: If you purchased Capricor securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a...
SAN FRANCISCO, Aug. 26, 2026 -- National investor rights law firm Hagens Berman highlights developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR). Following Capricor's recent Q2 2026 earnings release and conference call—notable for an omission of management Q&A...